Evidence map›Paper›PMID 38712082›Full record

ArticlebioRxiv : the preprint server for biology2025

PARP14 is an interferon (IFN)-induced host factor that promotes IFN production and affects the replication of multiple viruses.

Srivatsan Parthasarathy, Pradtahna Saenjamsai, Hongping Hao, Anna Ferkul, Jessica J Pfannenstiel, Daniel S Bejan, Yating Chen, Ellen L Suder, Nancy Schwarting, Masanori Aikawa and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Srivatsan ParthasarathyDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Pradtahna SaenjamsaiDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Hongping HaoDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Anna FerkulDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Jessica J PfannenstielDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Daniel S BejanDepartment of Chemical Physiology and Biochemistry, Oregon Health Sciences University, Portland, OR, 97239, USA.
Yating ChenDepartment of Molecular Biosciences, University of Texas, Austin, TX, 78712, USA.
Ellen L SuderDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, USA.
Nancy SchwartingDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Masanori AikawaCenter for Excellence in Vascular Biology (P.K.J., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Elke MuhlbergerDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, USA.
Adam J HumeDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, USA.
Robin C OrozcoDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.ORCID 0000-0002-2138-2912
Christopher S SullivanDepartment of Molecular Biosciences, University of Texas, Austin, TX, 78712, USA.
Michael S CohenDepartment of Chemical Physiology and Biochemistry, Oregon Health Sciences University, Portland, OR, 97239, USA.
David J DavidoDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.
Anthony R FehrDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA.ORCID 0000-0003-1560-1573

Funding

Whole Animal Imaging CoreUC7AI070088 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LEVIN, JAMES L · 2006 to 2013
$57.9M
BIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI JOHNSON, DAVID K · 2016 to 2025
$23.9M
Synthetic Chemical Biology CoreP30GM145499 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Susan M Lunte · 2022 to 2026
$6.9M
Determining mechanisms of innate immune modulation by ADP-ribosylationR35GM138029 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Anthony R Fehr · 2020 to 2026
$2.7M
Mechanisms of Marburg virus gene expressionR01AI133486 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FEARNS, RACHEL, MUHLBERGER, ELKE C · 2018 to 2022
$2.7M
PARP9 and PARP14 in atherosclerosisR01HL126901 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, MASANORI · 2016 to 2019
$2.4M
Non-coding RNA and ADP-ribosylation in Antiviral DefenseR01AI123231 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI SULLIVAN, CHRISTOPHER S. · 2017 to 2021
$1.9M
Elucidating the immune response of Schreiber's bats to Lloviu virus infection in vitro and in vivoR21AI169646 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MUHLBERGER, ELKE C · 2022 to 2023
$430k
Identifying the targets of virus-induced PARPs during SARS-CoV-2 infectionR21AI173781 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI COHEN, MICHAEL S, FEHR, ANTHONY R · 2023 to 2024
$424k
Investigating How ADP-ribosylation Impacts Innate Immunity During Coronavirus InfectionK22AI134993 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI FEHR, ANTHONY R · 2019 to 2020
$270k
NHLBI NIH HHS R01 HL126901NHLBI NIH HHS T32 HL007035NIAID NIH HHS K22 AI134993NIAID NIH HHS R01 AI123231NIAID NIH HHS R01 AI133486NIAID NIH HHS R21 AI169646NIAID NIH HHS UC7 AI070088NIGMS NIH HHS P20 GM113117NIGMS NIH HHS P30 GM145499NIGMS NIH HHS R35 GM138029
6 · The paper itself

Abstract

PARP14 is a 203 kDa multi-domain protein that is primarily known as an ADP-ribosyltransferase, and is involved in a variety of cellular functions including DNA damage, microglial activation, inflammation, and cancer progression. In addition, PARP14 is upregulated by interferon (IFN), indicating a role in the antiviral response. Furthermore, PARP14 has evolved under positive selection, again indicating that it is involved in host-pathogen conflict. We found that PARP14 is required for increased IFN-I production in response to coronavirus infection lacking ADP-ribosylhydrolase (ARH) activity and poly(I:C), however, whether it has direct antiviral function remains unclear. Here we demonstrate that the catalytic activity of PARP14 enhances IFN-

Indexed as

ADP-ribosylationcoronavirusEbola virusHSV-1interferoninterferon-stimulated genesLCMVmacrodomainNipah virusPARPVSV

Identifiers

PMID38712082
PMCPMC11071520

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.